ATLnsider,
This also goes a looooonnnnngggggg way towards explaining the interest in keeping the price low because the bear claim is there is no interest when in fact it is just the opposite. There is HUGE interest but no real leverage which is not a good look for big pharma. The first interest of course is in maintaining the current big pharma cash cow checkpoint inhibitor franchise for as long as possible. This means no openly public interest in NWBO by any big pharma or it’s game over, everyone for themselves all out bidding wars and loser consolidations. This would be to the peril of them all because of the price paid. Knowledge of what NWBO has is pure unadulterated potential POWER right now and that power has the potential to crush them so they can’t let on that they know that. They must look like they have leverage to move the little guy out of the way and they will fool some but the Jeffries analyst is obviously catching on to what is happening. NWBO longs proved their metal with the ASM vote too so buying NWBO cheap is not in the cards.
In one fell swoop the Linda ladies and the retail revolt will chastise Wall Street, fix cancer and tell the big money status quo and all their puppets they put in regulatory positions that their time is up.
I like it but big pharma and their hedgie friends don’t because they have Soooo much to lose. So all those folks too busy to look beyond next Q revenue growth, free cash flow, balances and market cap right now will be chasing up after the scraps that traders release at overbought points. While longs set generational assets aside after selling “1 or 2” shares to enjoy life and retirement with or give to charitable organizations to help meet needs much more important than a building built to memorialize a name on it bought with stolen money. Best wishes.
